X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with VENUS REMEDIES - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs VENUS REMEDIES - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA VENUS REMEDIES ASTRAZENECA PHARMA/
VENUS REMEDIES
 
P/E (TTM) x 104.7 -684.6 - View Chart
P/BV x 14.9 0.2 7,446.6% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ASTRAZENECA PHARMA   VENUS REMEDIES
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
VENUS REMEDIES
Mar-16
ASTRAZENECA PHARMA/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs1,285218 589.4%   
Low Rs63482 772.2%   
Sales per share (Unadj.) Rs189.6365.6 51.9%  
Earnings per share (Unadj.) Rs-0.21.5 -13.7%  
Cash flow per share (Unadj.) Rs3.837.9 10.1%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs68.6382.5 17.9%  
Shares outstanding (eoy) m25.0011.44 218.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.10.4 1,233.2%   
Avg P/E ratio x-4,712.7101.0 -4,667.2%  
P/CF ratio (eoy) x249.64.0 6,307.3%  
Price / Book Value ratio x14.00.4 3,563.7%  
Dividend payout %00-   
Avg Mkt Cap Rs m23,9881,717 1,397.4%   
No. of employees `0001.61.0 152.8%   
Total wages/salary Rs m1,605324 494.6%   
Avg. sales/employee Rs Th3,040.24,100.7 74.1%   
Avg. wages/employee Rs Th1,029.2318.0 323.6%   
Avg. net profit/employee Rs Th-3.316.7 -19.6%   
INCOME DATA
Net Sales Rs m4,7404,183 113.3%  
Other income Rs m9220 458.2%   
Total revenues Rs m4,8324,203 115.0%   
Gross profit Rs m-130812 -16.0%  
Depreciation Rs m101417 24.3%   
Interest Rs m0380 0.0%   
Profit before tax Rs m-13935 -395.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1390-   
Tax Rs m518 28.1%   
Profit after tax Rs m-517 -29.9%  
Gross profit margin %-2.719.4 -14.1%  
Effective tax rate %-3.751.6 -7.1%   
Net profit margin %-0.10.4 -26.4%  
BALANCE SHEET DATA
Current assets Rs m2,7262,771 98.4%   
Current liabilities Rs m2,4351,931 126.1%   
Net working cap to sales %6.120.1 30.6%  
Current ratio x1.11.4 78.0%  
Inventory Days Days74125 59.0%  
Debtors Days Days4154 75.8%  
Net fixed assets Rs m1,0355,328 19.4%   
Share capital Rs m50114 43.7%   
"Free" reserves Rs m9424,177 22.6%   
Net worth Rs m1,7164,376 39.2%   
Long term debt Rs m01,911 0.0%   
Total assets Rs m4,1568,428 49.3%  
Interest coverage xNM1.1-  
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x1.10.5 229.8%   
Return on assets %-0.14.7 -2.6%  
Return on equity %-0.30.4 -76.4%  
Return on capital %06.6 0.0%  
Exports to sales %5.70-   
Imports to sales %6.520.5 31.5%   
Exports (fob) Rs m270NA-   
Imports (cif) Rs m306858 35.7%   
Fx inflow Rs m3750-   
Fx outflow Rs m470858 54.8%   
Net fx Rs m-96-858 11.1%   
CASH FLOW
From Operations Rs m-8469 -1.7%  
From Investments Rs m-14629 -499.0%  
From Financial Activity Rs m862-464 -186.0%  
Net Cashflow Rs m70935 2,053.6%  

Share Holding

Indian Promoters % 0.0 32.9 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 0.2 166.7%  
FIIs % 15.7 0.6 2,706.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 66.4 13.7%  
Shareholders   12,856 20,121 63.9%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   ALEMBIC PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  TORRENT PHARMA  ALEMBIC LTD  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Trade Marginally Higher; IT Stocks Witness Buying Interest(11:30 am)

Stock markets in India are presently trading marginally higher. Sectoral indices are trading on a mixed note with stocks in the IT sector and FMCG sector witnessing maximum buying interest.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Feb 21, 2018 12:47 PM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA - CADILA HEALTHCARE COMPARISON

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS